In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
BACKGROUND: We have investigated a novel nonmyeloablative conditioning regimen in 44 patients with hematological malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. METHODS: Recipient conditioning c...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2001
|
| _version_ | 1826286252024922112 |
|---|---|
| author | Kottaridis, P Milligan, D Chopra, R Chakraverty, R Chakrabarti, S Robinson, S Peggs, K Verfuerth, S Pettengell, R Marsh, J Schey, S Mahendra, P Morgan, G Hale, G Waldmann, H de Elvira, R Williams, C Devereux, S Linch, D Goldstone, A MacKinnon, S |
| author_facet | Kottaridis, P Milligan, D Chopra, R Chakraverty, R Chakrabarti, S Robinson, S Peggs, K Verfuerth, S Pettengell, R Marsh, J Schey, S Mahendra, P Morgan, G Hale, G Waldmann, H de Elvira, R Williams, C Devereux, S Linch, D Goldstone, A MacKinnon, S |
| author_sort | Kottaridis, P |
| collection | OXFORD |
| description | BACKGROUND: We have investigated a novel nonmyeloablative conditioning regimen in 44 patients with hematological malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. METHODS: Recipient conditioning consisted of CAMPATH-1H 20 mg/day on Days -8 to -4, fludarabine 30 mg/m(2) on Days -7 to -3 and melphalan 140 mg/m(2) on Day -2. Thirty-six recipients received unmanipulated G-CSF mobilized PBSC from HLA identical siblings and eight received unmanipulated BM from MUD. GvHD prophylaxis was with CYA alone for 38 patients and CYA plus MTX for six sibling recipients. RESULTS: Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite PCR indicate that 18 of 31 patients studied were full donor chimeras, while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range, 3-29 months) 33 patients remain alive in CR, or with no evidence of disease progression. Seven patients relapsed or progressed post-transplant and four of them subsequently died. Four patients died from regimen-related complications. There were no cases of Grades III-IV acute GvHD. Only two patients developed Grade II acute GvHD and only one had chronic GvHD. The estimated probability of non-relapse mortality at 1 year was 11%.Results: Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity and low incidence of GvHD. |
| first_indexed | 2024-03-07T01:41:00Z |
| format | Journal article |
| id | oxford-uuid:96d5b37c-2d66-4249-9132-70d1ef58791b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:41:00Z |
| publishDate | 2001 |
| record_format | dspace |
| spelling | oxford-uuid:96d5b37c-2d66-4249-9132-70d1ef58791b2022-03-26T23:55:41ZIn vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:96d5b37c-2d66-4249-9132-70d1ef58791bEnglishSymplectic Elements at Oxford2001Kottaridis, PMilligan, DChopra, RChakraverty, RChakrabarti, SRobinson, SPeggs, KVerfuerth, SPettengell, RMarsh, JSchey, SMahendra, PMorgan, GHale, GWaldmann, Hde Elvira, RWilliams, CDevereux, SLinch, DGoldstone, AMacKinnon, S BACKGROUND: We have investigated a novel nonmyeloablative conditioning regimen in 44 patients with hematological malignancies. The median patient age was 41 years. Many of the patients had high-risk features, including 19 patients with a previous failed transplant. METHODS: Recipient conditioning consisted of CAMPATH-1H 20 mg/day on Days -8 to -4, fludarabine 30 mg/m(2) on Days -7 to -3 and melphalan 140 mg/m(2) on Day -2. Thirty-six recipients received unmanipulated G-CSF mobilized PBSC from HLA identical siblings and eight received unmanipulated BM from MUD. GvHD prophylaxis was with CYA alone for 38 patients and CYA plus MTX for six sibling recipients. RESULTS: Forty-two of the 43 evaluable patients had sustained engraftment. Results of chimerism analysis using microsatellite PCR indicate that 18 of 31 patients studied were full donor chimeras, while the other patients were mixed chimeras in one or more lineages. At a median follow-up of 9 months (range, 3-29 months) 33 patients remain alive in CR, or with no evidence of disease progression. Seven patients relapsed or progressed post-transplant and four of them subsequently died. Four patients died from regimen-related complications. There were no cases of Grades III-IV acute GvHD. Only two patients developed Grade II acute GvHD and only one had chronic GvHD. The estimated probability of non-relapse mortality at 1 year was 11%.Results: Although longer follow-up is needed to establish the long-term remission rates, this study demonstrates that this nonmyeloablative preparative regimen is associated with durable engraftment, minimal toxicity and low incidence of GvHD. |
| spellingShingle | Kottaridis, P Milligan, D Chopra, R Chakraverty, R Chakrabarti, S Robinson, S Peggs, K Verfuerth, S Pettengell, R Marsh, J Schey, S Mahendra, P Morgan, G Hale, G Waldmann, H de Elvira, R Williams, C Devereux, S Linch, D Goldstone, A MacKinnon, S In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. |
| title | In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. |
| title_full | In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. |
| title_fullStr | In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. |
| title_full_unstemmed | In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. |
| title_short | In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. |
| title_sort | in vivo campath 1h prevents gvhd following nonmyeloablative stem cell transplantation |
| work_keys_str_mv | AT kottaridisp invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT milligand invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT choprar invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT chakravertyr invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT chakrabartis invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT robinsons invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT peggsk invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT verfuerths invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT pettengellr invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT marshj invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT scheys invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT mahendrap invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT morgang invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT haleg invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT waldmannh invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT deelvirar invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT williamsc invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT devereuxs invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT linchd invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT goldstonea invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation AT mackinnons invivocampath1hpreventsgvhdfollowingnonmyeloablativestemcelltransplantation |